Is Blood Pressure Reduction Beneficial in Stroke?

by Dr. Simi Paknikar on  March 04, 2011 at 5:44 PM Health Watch
  •   Print
  •   Share
  •   Comments
  •  Text 
High blood pressure increases the risk of developing stroke. Patients with hypertension often have stiffened arteries, due to deposition of cholesterol, the condition known as atherosclerosis. Very high blood pressure could also lead to bleeding within the brain, resulting in stroke. Treatment of hypertension is associated with a decrease in stroke. However, it is not yet clear whether reducing blood pressure in patients who have already suffered from a stroke is beneficial.

Patients who suffer from stroke often have a high blood pressure. The high blood pressure in these patients could be due to prior hypertension, stress, damage to the brain or a rise in pressure around the brain. High blood pressure in stroke patients has been shown to increase the risk of brain edema and bleeding in the brain. However, some researchers feel that reducing blood pressure in such patients lead to decrease in blood supply to the brain and can further worsen stroke. Studies with a calcium channel blocker nimodipine have indicated that reduction of blood pressure in stroke patients can further add to the damage.

Candesartan is a blood pressure lowering drug belonging to the group of angiotensin II receptor blockers. A recent study was conducted to find out if candesartan provides benefit in stroke patients by reducing blood pressure. The patients were followed to determine if they experienced changes in functional outcomes or if they suffered from further complications like stroke, heart attack and death.

The researchers found that reducing blood pressure does not provide beneficial effects in these patients. In fact, it may have some harmful effect especially in functional outcomes.

Further studies using different blood pressure lowering drugs may be required to establish their role in the treatment of stroke.

Reference

  1. Harrison’s Principles of Internal Medicine 17th edition


  2. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. The SCAST Study Group. The Lancet, Volume 377, Issue 9767, Pages 741 - 750, 26 February 2011


Source-Medindia

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Senior Health Center

Health Watch News

» Omega-3 and Omega-6 Fatty Acids Provide Health Benefits Throughout Life » Nutritional Treatments as Good Targets of Gut-Central Nervous System Axis
» Sleep Longer to Prevent Weight Gain » Managing Prostate Cancer With Focal Therapy
» 'Healthy Dads Healthy Kids' - A Weight Loss Model to Avoid Obesity for Healthy Lifestyle » Influence of Diet and Toxins in Autism Epidemic
» Antipsychotic Drugs and Relapsing Schizophrenia » Viruses can Result in Acute Attacks of Chronic Lung Diseases
Read More >>